Abstract
Background Dysregulated inflammation with superimposed malnutrition may constitute a significant threat in acute coronary syndrome (ACS), which needs to be elucidated. We aimed to explore the prevalence and combined predictive value of inflammation and malnutrition in ACS patients.
Methods Patients presenting with ACS undergoing percutaneous coronary intervention (PCI) were retrospectively included and stratified into four groups: nourished without elevated high-sensitivity C-reactive protein (hs-CRP), nourished with elevated hs-CRP, malnourished without elevated hs-CRP, and malnourished with elevated hs-CRP. Elevated hs-CRP was determined as over 2.2mg/L, and malnutrition was defined according to the nutritional risk index (NRI). The primary outcome was major adverse cardiovascular events (MACEs), the composite of cardiac mortality, non-fatal myocardial infarction, non-fatal stroke, and unplanned revascularization.
Results A total of 1,743 patients were ultimately included; 646 (37%) presented elevated hs-CRP, and 119 (7%) were considered malnourished. During a median follow-up of 30 months, 351 (20.1%) MACEs occurred. The coexistence of malnutrition and elevated hs-CRP correlated with the worst outcomes among the four phenotypes, with a significantly increased risk of MACEs (adjusted hazard ratio: 2.446; 95% confidence interval: 1.464 - 4.089; p <0.001). In the subgroup analysis, NRI displayed MACEs-predicting value merely among patients with elevated hs-CRP rather than those without (p for interaction = 0.005), suggesting the modifying effect of inflammation; simultaneously, the prognostic implications of hs-CRP were influenced by patients’ baseline nutritional status, as it only existed in malnourished patients (p for interaction < 0.001).
Conclusions Among patients with ACS undergoing PCI, the double burden of inflammation and malnutrition signifies poorer outcomes, and their prognostic implications may be amplified by each other, which would provide implications to facilitate more individualized ACS care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Beijing Municipal Natural Science Foundation, General Program (7232039), and the Capital Health Research and Development of Special (2022-2-1052).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study followed the Helsinki Declaration of Human Rights and was approved by the institutional review board (IRB) of Beijing Anzhen Hospital (IRB number: 2016034x). The IRB waived the need for written patient consent as this study involved a retrospective analysis of clinically acquired data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datesets uesd and/or analyzed during the current study are avalible from the corresponding author on reasonable request.
